Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ:BIIB) and its Alzheimer's med, Aduhelm (aducanumab).
- According to the Company's annual filing, the FTC has made a civil investigative demand in pursuit of documents related to Aduhelm's marketing and approval, plus healthcare sites, the Company said.
- Also See: After Much Criticism, Biogen Slashes Aduhelm Price In Half.
- The SEC, meanwhile, has launched a separate inquiry that also seeks marketing and approval information on the beleaguered anti-amyloid antibody.
- The lawmakers have also asked the FDA to produce additional data and documentation supporting its accelerated approval for the drug.
- Aduhelm's rocky rollout has translated into poor sales, too. The drug made just $1 million for the fourth quarter and $3 million for 2021.
- Price Action: BIIB shares are trading 0.91% higher at $222.17 during the market session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!